ArticleFrontiers in medicine2025
Ultrastructure of human platelet concentrates after treatment with pathogen reduction technologies for prolonged storage.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Pathogen reduction technologies (PRTs) increase blood supply safety but may also increase platelet storage lesion, probably due to mitochondrial DNA damage. The purpose of this study was to investigate whether these changes are morphologically detectable. Materials and methods: Blood platelets were obtained by triple-dose apheresis collection ( Results: Freshly isolated platelets (0 days storage) contained 2.4% mitochondria (volume density) and 4.5% CS (volume density). After 1 day of storage mitochondrial volume density was reduced to 1.5% in untreated, 1.3% in INTERCEPT-treated and 1.6% in MIRASOL-treated platelet concentrates, i.e., a loss of up to 37% of mitochondrial volume regardless of treatment. After 7 days storage mitochondrial volume density was 1.3, 1.3 and 1.5% respectively; neither at 1 nor at 7 days storage were any noteworthy differences between untreated, INTERCEPT or MIRASOL-treated platelets. In stark contrast to mitochondria the CS ballooned up to 88% in all groups. After 1 day of storage CS volume density was increased to 8.6% in untreated, 8.4% in INTERCEPT-treated and 7.0% in MIRASOL-treated platelet concentrates. After 7 days storage CS volume density was 8.0, 8.3 and 6.3% respectively; neither at 1 nor at 7 days storage were significant differences between untreated, INTERCEPT or MIRASOL-treated platelets. Only at 7 days a slight tendency of a smaller CS in MIRASOL versus INTERCEPT and untreated CONTROL groups was observed. Conclusion: Platelet mitochondrial volume shrinks and canalicular system swells within the first 24 h after collection and then both remain rather constant for up to seven days with or without PRT treatment. Pathogen reduction technology - both INTERCEPT and MIRASOL - does not increase morphological platelet storage lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.